Matches in DBpedia 2016-04 for { <http://dbpedia.org/resource/Brigatinib> ?p ?o }
Showing triples 1 to 65 of
65
with 100 triples per page.
- Brigatinib abstract "Brigatinib (previously known as AP26113) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). ARIAD has begun a Phase 1/2 clinical trial of brigatinib based on cancer patients’ molecular diagnoses in September 2011. ALK was first identified as a chromosomal rearrangement in anaplastic large cell lymphoma (ALCL). Genetic studies indicate that abnormal expression of ALK is a key driver of certain types of non-small cell lung cancer (NSCLC) and neuroblastomas, as well as ALCL. Since ALK is generally not expressed in normal adult tissues, it represents a highly promising molecular target for cancer therapy.Epidermal growth factor receptor (EGFR) is another validated target in NSCLC. Additionally, the T790M “gatekeeper” mutation is linked in approximately 50 percent of patients who grow resistant to first-generation EGFR inhibitors. While second-generation EGFR inhibitors are in development, clinical efficacy has been limited due to toxicity thought to be associated with inhibiting the native (endogenous or unmutated) EGFR. A therapy designed to target EGFR, the T790M mutation but avoiding inhibition of native EGFR is another promising molecular target for cancer therapy.".
- Brigatinib iupacName "5-Chloro-N2-{4-[4-(dimethylamino)-1-piperidinyl]-2-methoxyphenyl}-N4-[2-(dimethylphosphoryl)phenyl]-2,4-pyrimidinediamine".
- Brigatinib thumbnail Brigatinib.svg?width=300.
- Brigatinib wikiPageID "32614566".
- Brigatinib wikiPageLength "4645".
- Brigatinib wikiPageOutDegree "17".
- Brigatinib wikiPageRevisionID "703438447".
- Brigatinib wikiPageWikiLink ALK_inhibitor.
- Brigatinib wikiPageWikiLink ARIAD_Pharmaceuticals.
- Brigatinib wikiPageWikiLink Anaplastic_large-cell_lymphoma.
- Brigatinib wikiPageWikiLink Category:Experimental_cancer_drugs.
- Brigatinib wikiPageWikiLink Category:Phosphine_oxides.
- Brigatinib wikiPageWikiLink Category:Piperidines.
- Brigatinib wikiPageWikiLink Category:Protein_kinase_inhibitors.
- Brigatinib wikiPageWikiLink Category:Pyrimidines.
- Brigatinib wikiPageWikiLink Drug_development.
- Brigatinib wikiPageWikiLink Epidermal_growth_factor_receptor.
- Brigatinib wikiPageWikiLink Neuroblastoma.
- Brigatinib wikiPageWikiLink Non-small-cell_lung_carcinoma.
- Brigatinib wikiPageWikiLink Small_molecule.
- Brigatinib wikiPageWikiLink T790M.
- Brigatinib wikiPageWikiLink Targeted_therapy.
- Brigatinib wikiPageWikiLinkText "Brigatinib".
- Brigatinib imagefile "Brigatinib.svg".
- Brigatinib imagesize "250".
- Brigatinib iupacname "5".
- Brigatinib othernames "AP26113".
- Brigatinib wikiPageUsesTemplate Template:COI.
- Brigatinib wikiPageUsesTemplate Template:Chembox.
- Brigatinib wikiPageUsesTemplate Template:Chembox_Hazards.
- Brigatinib wikiPageUsesTemplate Template:Chembox_Identifiers.
- Brigatinib wikiPageUsesTemplate Template:Chembox_Properties.
- Brigatinib wikiPageUsesTemplate Template:Full.
- Brigatinib wikiPageUsesTemplate Template:Multiple_issues.
- Brigatinib wikiPageUsesTemplate Template:Reflist.
- Brigatinib wikiPageUsesTemplate Template:Third-party.
- Brigatinib subject Category:Experimental_cancer_drugs.
- Brigatinib subject Category:Phosphine_oxides.
- Brigatinib subject Category:Piperidines.
- Brigatinib subject Category:Protein_kinase_inhibitors.
- Brigatinib subject Category:Pyrimidines.
- Brigatinib hypernym Therapy.
- Brigatinib type ChemicalCompound.
- Brigatinib type ChemicalSubstance.
- Brigatinib type Drug.
- Brigatinib type Alkyne.
- Brigatinib type Heterocycle.
- Brigatinib type Hydrocarbon.
- Brigatinib type Inhibitor.
- Brigatinib type Organofluoride.
- Brigatinib type Organohalide.
- Brigatinib type Organofluoride.
- Brigatinib type Organohalide.
- Brigatinib type ChemicalObject.
- Brigatinib type Thing.
- Brigatinib type Q11173.
- Brigatinib comment "Brigatinib (previously known as AP26113) is an investigational small-molecule targeted cancer therapy being developed by ARIAD Pharmaceuticals, Inc. Brigatinib has exhibited activity as a potent dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). ARIAD has begun a Phase 1/2 clinical trial of brigatinib based on cancer patients’ molecular diagnoses in September 2011.".
- Brigatinib label "Brigatinib".
- Brigatinib sameAs Q4653190.
- Brigatinib sameAs m.013b1443.
- Brigatinib sameAs m.0h1ckcz.
- Brigatinib sameAs Q4653190.
- Brigatinib wasDerivedFrom Brigatinib?oldid=703438447.
- Brigatinib depiction Brigatinib.svg.
- Brigatinib isPrimaryTopicOf Brigatinib.